MedPath

Equol

Generic Name
Equol
Drug Type
Small Molecule
Chemical Formula
C15H14O3
CAS Number
531-95-3
Unique Ingredient Identifier
2T6D2HPX7Q
Background

Equol has been used in trials studying the treatment of Breast Cancer.

Clinical Trials
Related News

Acute Equol Supplementation and Vascular Function in Women With and Without CKD

Phase 2
Recruiting
Conditions
Chronic Kidney Diseases
Interventions
First Posted Date
2023-11-13
Last Posted Date
2024-08-23
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
38
Registration Number
NCT06128278
Locations
🇺🇸

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers

Phase 2
Active, not recruiting
Conditions
White Matter Lesions
Arterial Stiffness
Cognitive Decline
Interventions
Drug: Placebo
First Posted Date
2023-02-23
Last Posted Date
2024-11-08
Lead Sponsor
Akira Sekikawa
Target Recruit Count
372
Registration Number
NCT05741060
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

S-Equol in Alzheimer's Disease 2 Trial

Phase 1
Completed
Conditions
Alzheimer Disease
Interventions
First Posted Date
2017-04-04
Last Posted Date
2024-07-25
Lead Sponsor
Russell Swerdlow
Target Recruit Count
40
Registration Number
NCT03101085
Locations
🇺🇸

Clinical and Translational Science Unit, Fairway, Kansas, United States

🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

S-equol in Women With Triple Negative Breast Cancer

Early Phase 1
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2015-01-30
Last Posted Date
2020-07-22
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
39
Registration Number
NCT02352025
Locations
🇺🇸

CTRC (Cancer Therapy and Research Center) at UTHSCSA, San Antonio, Texas, United States

Multi-Dose Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2009-10-21
Last Posted Date
2012-07-12
Lead Sponsor
Ausio Pharmaceuticals, LLC
Target Recruit Count
41
Registration Number
NCT00998920
Locations
🇺🇸

Charles River, Tacoma, Washington, United States

Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients

Phase 2
Completed
Conditions
Menopause
Interventions
Drug: Placebo
First Posted Date
2009-08-20
Last Posted Date
2014-04-08
Lead Sponsor
Ausio Pharmaceuticals, LLC
Target Recruit Count
169
Registration Number
NCT00962585
Locations
🇺🇸

Greater Cincinnati OB/GYN, Inc., Cincinnati,, Ohio, United States

🇺🇸

Radiant Research, Inc, Greenville, South Carolina, United States

🇦🇺

Royal Hospital for Women, Randwick, New South Wales, Australia

and more 6 locations

Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia

Phase 2
Completed
Conditions
Benign Prostatic Hyperplasia
Interventions
Drug: Placebo
First Posted Date
2009-08-20
Last Posted Date
2017-05-19
Lead Sponsor
Ausio Pharmaceuticals, LLC
Target Recruit Count
116
Registration Number
NCT00962390
Locations
🇮🇳

Indraprastha Apollo Hospital, Delhi, India

🇮🇳

Samved Hospital, Ahmedabad, India

🇮🇳

M S Ramaiah Memorial Hospital, Bangalore, India

and more 12 locations

Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2008-11-07
Last Posted Date
2012-01-20
Lead Sponsor
Ausio Pharmaceuticals, LLC
Target Recruit Count
60
Registration Number
NCT00787007
Locations
🇺🇸

Charles River, Tacoma, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy